Sanofi promises to invest $20 billion in the United States

And one more. Following the Americans Lilly, Johnson & Johnson, AbbVie, Bristol Myers Squibb, and Gilead, the Swiss Roche and Novartis, as well as the Japanese Takeda, who together announced nearly $250 billion (€223.7 billion) of investments in the United States in recent months, Sanofi is also bowing to pressure from Washington. The French pharmaceutical laboratory announced on Wednesday, May 14, its intention to invest "at least $20 billion" across the Atlantic over the next five years.

"This planned investment includes a significant increase in research and development spending and the allocation of billions of dollars to American production," announced the French group, which specified that these amounts will be adjusted according to the evolution of the external environment.

The pharmaceutical company, which generated nearly 49% of its sales in the United States in 2024, is the first Big Pharma in the European Union to join the ranks of drugmakers ready to sign a large check in the country.

You have 59.74% of this article left to read. The rest is reserved for subscribers.